Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327298 | 1.00 | PLA2G10 (0.45) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL10326470 | 1.00 | PLA2G10 (0.45) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL3917588 | 0.83 | PLA2G10 (0.39) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL4041207 | 0.81 | PLA2G10 (0.38) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL4016339 | 0.79 | PLA2G10 (0.49) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL3003268 | 0.79 | PLA2G10 (0.49) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL10326657 | 0.79 | PLA2G10 (0.49) | PLA2G10PLA2G5HDAC8GAAPOLB | |
| SCHEMBL4041320 | 0.79 | PLA2G10 (0.38) | PLA2G10PLA2G5HDAC8GAACXCR3 | |
| SCHEMBL1801279 | 0.79 | ALDH1A1 (0.39) | PLA2G10PLA2G5GAATACR1ALDH1A1 | |
| SCHEMBL3927073 | 0.79 | DPP7 (0.50) | GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | PLA2G10 2953/4885PLA2G5 806/4885HDAC8 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.